ES2755449T3 - Compuestos para aumentar la semi-vida del factor von Willebrand - Google Patents

Compuestos para aumentar la semi-vida del factor von Willebrand Download PDF

Info

Publication number
ES2755449T3
ES2755449T3 ES16708978T ES16708978T ES2755449T3 ES 2755449 T3 ES2755449 T3 ES 2755449T3 ES 16708978 T ES16708978 T ES 16708978T ES 16708978 T ES16708978 T ES 16708978T ES 2755449 T3 ES2755449 T3 ES 2755449T3
Authority
ES
Spain
Prior art keywords
antibody
clec10a
vwf
binding
fviii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16708978T
Other languages
English (en)
Spanish (es)
Inventor
Michael Moses
Stefan Schulte
Gerhard Dickneite
Uwe Kalina
Sabine Pestel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CSL Behring Lengnau AG
Original Assignee
CSL Behring Lengnau AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CSL Behring Lengnau AG filed Critical CSL Behring Lengnau AG
Application granted granted Critical
Publication of ES2755449T3 publication Critical patent/ES2755449T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ES16708978T 2015-03-06 2016-03-04 Compuestos para aumentar la semi-vida del factor von Willebrand Active ES2755449T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15158088 2015-03-06
PCT/EP2016/054650 WO2016142289A1 (en) 2015-03-06 2016-03-04 Compounds for improving the half-life of von willebrand factor

Publications (1)

Publication Number Publication Date
ES2755449T3 true ES2755449T3 (es) 2020-04-22

Family

ID=52629453

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16708978T Active ES2755449T3 (es) 2015-03-06 2016-03-04 Compuestos para aumentar la semi-vida del factor von Willebrand

Country Status (12)

Country Link
US (1) US20180043012A1 (enExample)
EP (1) EP3265489B1 (enExample)
JP (1) JP6704420B2 (enExample)
KR (1) KR20170125942A (enExample)
CN (1) CN107428831A (enExample)
AU (1) AU2016231328B2 (enExample)
BR (1) BR112017017852A2 (enExample)
CA (1) CA2978134A1 (enExample)
DK (1) DK3265489T3 (enExample)
ES (1) ES2755449T3 (enExample)
SG (1) SG11201706657PA (enExample)
WO (1) WO2016142289A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4217402A1 (en) * 2020-09-23 2023-08-02 Ablevia biotech GmbH Compound for the prevention or treatment of autoantibody-mediated conditions
EP4251272A4 (en) * 2020-11-24 2024-10-09 Band Therapeutics, LLC COMPOSITIONS AND METHODS FOR THE TREATMENT OF BLEEDING DISORDERS
CN116723863A (zh) * 2020-11-24 2023-09-08 邦德治疗有限公司 用于治疗出血性病症的组合物和方法
CN121991252B (zh) * 2026-04-09 2026-07-17 重庆臻伽亦生物科技有限公司 一种基于优化肽接头的多价cd301融合蛋白、功能化磁珠及其在ctc捕获中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
PT1754718E (pt) * 1996-04-24 2011-07-13 Univ Michigan Factor viii resistente à inactivação
CA2465004A1 (en) * 2003-05-19 2004-11-19 National Institute For Biological Standards And Control Composition
JP2005132796A (ja) * 2003-10-31 2005-05-26 Tatsuro Irimura 肉芽組織形成性疾患の治療のための医薬組成物および方法
EP1593388A1 (en) * 2004-05-05 2005-11-09 ZLB Behring GmbH Therapeutic plasma protein-concentrates containing von willebrand factor as high molecular weight multimers
EP2662083A1 (en) * 2012-05-08 2013-11-13 CSL Behring GmbH Sugar compositions for treating hemophilia a and/or von willebrand disease
EP2669679A1 (en) * 2012-05-28 2013-12-04 Universitätsklinikum Hamburg-Eppendorf Method for the detection of glycans using polypeptides comprising the CD301 carbohydrate recognition domain
ES2770501T3 (es) * 2012-07-11 2020-07-01 Bioverativ Therapeutics Inc Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos
KR20230007555A (ko) * 2013-06-28 2023-01-12 바이오버라티브 테라퓨틱스 인크. Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도

Also Published As

Publication number Publication date
EP3265489A1 (en) 2018-01-10
WO2016142289A1 (en) 2016-09-15
JP2018510213A (ja) 2018-04-12
CN107428831A (zh) 2017-12-01
KR20170125942A (ko) 2017-11-15
US20180043012A1 (en) 2018-02-15
JP6704420B2 (ja) 2020-06-03
SG11201706657PA (en) 2017-09-28
CA2978134A1 (en) 2016-09-15
AU2016231328B2 (en) 2018-07-05
DK3265489T3 (da) 2019-07-15
BR112017017852A2 (pt) 2018-04-10
EP3265489B1 (en) 2019-05-08
AU2016231328A1 (en) 2017-10-26

Similar Documents

Publication Publication Date Title
Stennicke et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
US20220135959A1 (en) Chimeric clotting factors
US20200354459A1 (en) ANTI-GLYCOPROTEIN IIb/IIIa ANTIBODIES
ES2755376T3 (es) Anticuerpos monoclonales anti-factor XI y métodos de uso de los mismos
ES2772933T3 (es) Factor de von Willebrand modificado que tiene una semivida mejorada
US10364288B2 (en) Anti-GPIIB/IIIA antibodies or uses thereof
US20210246212A1 (en) Anti-gpiib/iiia antibodies and uses thereof
EA034050B1 (ru) Модифицированные серпины для лечения нарушений свертываемости крови
EP3515948A1 (en) Coagulation factor binding proteins and uses thereof
AU2016231328B2 (en) Compounds for improving the half-life of von Willebrand factor
ES2729737T3 (es) Composiciones de azúcar para tratamiento de la hemofilia A y/o la enfermedad de Von Willebrand
US20190169307A1 (en) Glycoprotein v inhibitors for use as coagulants
HK1245301B (en) Compounds for improving the half-life of von willebrand factor
HK1245301A1 (en) Compounds for improving the half-life of von willebrand factor
RU2817219C2 (ru) Новые гуманизированные антитела к фактору xi с антитромботическим и противовоспалительным действием и их применение
FVIII A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models
KR102785415B1 (ko) 혈전성 질환을 치료하기 위한 가용성 당단백질 v
HK1244292B (en) Modified von willebrand factor having improved half-life